Pr BOURA Cédric

Fiche personne

coordonnées

Centre de Recherche en Automatique de Nancy (CRAN)
UMR7039 Université de Lorraine-CNRS
Département Santé-Biologie-Signal (SBS)
Faculté de Médecine
9 avenue de la Forêt de Haye
BP 184
54505 VANDOEUVRE-LES-NANCY Cedex

03 83 74 61 10

cedric.boura@univ-lorraine.fr

Territoire

Lorraine

Statut

Enseignant-Chercheur

affiliation

Université de Lorraine (UL)

Centre de Recherche en Automatique de Nancy (CRAN) - UMR 7039 (CRAN)

équipes/plateformes

Equipe UMR 7039 - Equipe "Biologie, Signaux et Systèmes en Cancérologie et Neurosciences (BioSIS)"

Projets

Efficacité anti-tumorale d’une stratégie CAR-T cell anti-GD2 optimisée dans l’environnement immunosuppresseur du glioblastome (BOOSTCAR)

2022 - Porteur du projet : Dr REPPEL Loïc - Partenaires : Dr PINEL Sophie, Pr BOURA Cédric

Evaluation in vivo d’un composé peptidomimétique dirigé contre la Neuropiline-1 en association avec la radiothérapie pour le traitement du médulloblastome

2017 - Porteur du projet : Pr BOURA Cédric

Amélioration des performances du macroscope AZ100 pour l'imagerie de fluorescence en champs large

2015 - Porteur du projet : Pr BOURA Cédric

Publications

NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells.

Douyère M, Gong C, Richard M, Pellegrini-Moïse N, Daouk J, Pierson J, Chastagner P, Boura C

Cancer Cell Int. 2022 12 1;22(1):377

Clickable -Glycosyl Scaffold for the Development of a Dual Fluorescent and [F]fluorinated Cyanine-Containing Probe and Preliminary In Vitro/Vivo Evaluation by Fluorescence Imaging.

Ariztia J, Jouad K, Jouan-Hureaux V, Pierson J, Collet C, Kuhnast B, Selmeczi K, Boura C, Lamandé-Langle S, Pellegrini Moïse N

Pharmaceuticals (Basel). 2022 11 29;15(12):

tLyp-1: A peptide suitable to target NRP-1 receptor.

Larue L, Kenzhebayeva B, Al-Thiabat MG, Jouan-Hureaux V, Mohd-Gazzali A, Wahab HA, Boura C, Yeligbayeva G, Nakan U, Frochot C, Acherar S

Bioorg Chem. 2022 10 23;130:106200

Synthesis of anti-proliferative [3.3.0]furofuranone derivatives by lactonization and functionalization of C-glycosyl compounds.

Ariztia J, Chateau A, Boura C, Didierjean C, Lamandé-Langle S, Pellegrini Moïse N

Bioorg Med Chem. 2021 Jul 21;45:116313

Natural Killer cells and monoclonal antibodies: two partners for successful antibody dependent cytotoxicity against tumor cells.

Gauthier M, Laroye C, Bensoussan D, Boura C, Decot V

Crit Rev Oncol Hematol. 2021 Feb 16;:103261

Design of a Targeting and Oxygen-Independent Platform to Improve Photodynamic Therapy: A Proof of Concept.

Larue L, Moussounda Moussounda Koumba T, Le Breton N, Vileno B, Arnoux P, Jouan-Hureaux V, Boura C, Audran G, Bikanga R, Marque SRA, Acherar S, Frochot C

ACS Appl Bio Mater. 2021 Feb 15;4(2):1330-1339

Synthesis of a DOTA--glyco bifunctional chelating agent and preliminary and study of [Ga]Ga-DOTA--glyco-RGD.

Mangin F, Collet C, Jouan-Hureaux V, Maskali F, Roeder E, Pierson J, Selmeczi K, Marie PY, Boura C, Pellegrini-Moïse N, Lamandé-Langle S

RSC Adv. 2021 Feb 10;11(13):7672-7681

Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.

Douyère M, Chastagner P, Boura C

Front Oncol. 2021 ;11:665634

Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment.

Pinel S, Thomas N, Boura C, Barberi-Heyob M

Adv. Drug Deliv. Rev.. 2018 Nov 7;:

Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1.

Gong C, Valduga J, Chateau A, Richard M, Pellegrini-Moïse N, Barberi-Heyob M, Chastagner P, Boura C

Oncotarget. 2018 Mar 16;9(20):15312-15325

Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application.

Kamarulzaman EE, Vanderesse R, Gazzali AM, Barberi-Heyob M, Boura C, Frochot C, Shawkataly O, Aubry A, Wahab HA

J. Biomol. Struct. Dyn.. 2017 Jan;35(1):26-45

Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma.

Thomas E, Colombeau L, Gries M, Peterlini T, Mathieu C, Thomas N, Boura C, Frochot C, Vanderesse R, Lux F, Barberi-Heyob M, Tillement O

Int J Nanomedicine. 2017 ;12:7075-7088

Carbohydrate-based peptidomimetics targeting neuropilin-1: Synthesis, molecular docking study and in vitro biological activities.

Richard M, Chateau A, Jelsch C, Didierjean C, Manival X, Charron C, Maigret B, Barberi-Heyob M, Chapleur Y, Boura C, Pellegrini-Moïse N

Bioorg. Med. Chem.. 2016 Nov;24(21):5315-5325

Sensitivity of glioma initiating cells to a monoclonal anti-EGFR antibody therapy under hypoxia.

Randriarimanana T, Chateau A, Faivre B, Pinel S, Boura C

Life Sci. 2015 Sep 15;137:74-80

New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy.

Kamarulzaman EE, Gazzali AM, Acherar S, Frochot C, Barberi-Heyob M, Boura C, Chaimbault P, Sibille E, Wahab HA, Vanderesse R

Int J Mol Sci. 2015 Oct 12;16(10):24059-80

PTEN expression is involved in the invasive properties of HNSCC: a key protein to consider in locoregional recurrence.

Mriouah J, Boura C, Gargouri M, Plénat F, Faivre B

Int. J. Oncol.. 2014 Mar;44(3):709-16

Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models.

Mriouah J, Boura C, Thomassin M, Bastogne T, Dumas D, Faivre B, Barberi-Heyob M

Trends Biotechnol. 2012 Dec;30(12):649-58

Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.

Jouan-Hureaux V, Boura C, Merlin JL, Faivre B

Microvasc. Res.. 2012 Mar;83(2):131-7

Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.

Mriouah J, Boura C, Pinel S, Chretien AS, Fifre A, Merlin JL, Faivre B

Int. J. Oncol.. 2010 Dec;37(6):1555-63

Re-endothelialization of human umbilical arteries treated with polyelectrolyte multilayers: A tool for damaged vessel replacement

Kerdjoudj H, Boura C, Moby V, Montagne K, Schaaf P, Voegel JC, Stoltz JF, Menu P

Adv Funct Mater. 2007 Oct 15;17(15):2667-73

Poly(styrenesulfonate)/poly(allylamine) multilayers: a route to favor endothelial cell growth on expanded poly(tetrafluoroethylene) vascular grafts.

Moby V, Boura C, Kerdjoudj H, Voegel JC, Marchal L, Dumas D, Schaaf P, Stoltz JF, Menu P

Biomacromolecules. 2007 Jul;8(7):2156-60

In vitro impact of physiological shear stress on endothelial cells gene expression profile.

Gaucher C, Devaux C, Boura C, Lacolley P, Stoltz JF, Menu P

Clin. Hemorheol. Microcirc.. 2007 ;37(1-2):99-107

The ideal small arterial substitute: Role of cell seeding and tissue engineering.

Kerdjoudj H, Moby V, Berthelemy N, Gentils M, Boura C, Bordenave L, Stoltz JF, Menu P

Clin. Hemorheol. Microcirc.. 2007 ;37(1-2):89-98

Decellularized umbilical artery treated with thin polyelectrolyte multilayer films: potential use in vascular engineering.

Kerdjoudj H, Boura C, Marchal L, Dumas D, Schaff P, Voegel JC, Stoltz JF, Menu P

Biomed Mater Eng. 2006;16(4 Suppl):S123-9.

Endothelial cells grown on thin polyelectrolyte mutlilayered films: an evaluation of a new versatile surface modification.

Boura C, Menu P, Payan E, Picart C, Voegel JC, Muller S, Stoltz JF

Biomaterials. 2003 Sep;24(20):3521-30

Volume expansion with modified hemoglobin solution, colloids, or crystalloid after hemorrhagic shock in rabbits: effects in skeletal muscle oxygen pressure and use versus arterial blood velocity and resistance.

Boura C, Caron A, Longrois D, Mertes PM, Labrude P, Menu P

Shock. 2003 Feb;19(2):176-82